Showing results (11-20 of 77) with videos related to

Sort By:
Pageof 8
Leukemia & Lymphoma|August 1, 1994
Long term results of interferon treatment in hairy cell leukemia. Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL)G Capnist, M Federico, T Chisesi, et al.
British Journal of Haematology|May 1, 1989
Human lymphoblastoid interferon as initial therapy in hairy cell leukaemia: a multicentre study in non-splenectomized patients. Italian Cooperative Group for Hairy Cell LeukemiaM Federico, T Chisesi, F Lauria, et al.
Leukemia|January 1, 1991
ProMACE-MOPP vs MACOP-B in high grade non-Hodgkin's lymphomas: a randomised study in a multicenter cooperative study group (NHLCSG)T Chisesi, G Santini, G Capnist, et al.
Leukemia Research|January 1, 1991
Should alpha interferon be used as primary treatment for hairy cell leukemia? Italian Cooperative Group for Hairy Cell LeukemiaG Capnist, M Federico, T Chisesi, et al.
Leukemia & Lymphoma|July 28, 2016
Treatment of Early Stage Hodgkin's Disease According to Risk FactorsT Chisesi, M Vespignani, G Capnist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1994
Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCLM Federico, A Frassoldati, T Lamparelli, et al.
Leukemia & Lymphoma|January 1, 1993
The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) ItalyT Chisesi
Oncology|January 1, 1990
Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patientsP Bevilacqua, G Gasparini, S Dal Fior, et al.
Breast Cancer Research and Treatment|December 1, 1989
Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinomaG Gasparini, S Dal Fior, F Pozza, et al.
American Journal of Clinical Oncology|February 1, 1991
Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trialG Gasparini, S Dal Fior, G A Panizzoni, et al.
Pageof 8